SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pojak watched as the world played hot potato with CTO shit coins. Now, it's his moment. With Pepe's legendary meme power and Wojak's emotional depth, Pojak brings a new level of influence, wealth, and ethics. Born into meme royalty with luxury and wisdom from Pepe and Wojak, he faced hardship when the original developer rugged the project. The community rose up and took control. Pojak was reborn, stronger and more determined.

Pojak

PJ CRYPTO ($PJ) is trending as it gains traction within the Phantom Wallet community. The community highlights its strong chart and growing momentum, viewing it as an opportunity for early movers. Some caution is being advised as well.

Solana Street Bets is not just a memecoin; it's a symbol of creativity, humor, and the power of a united community. Inspired by the infamous /wallstreetbets subreddit. Solana Street Bets is here to put respect on the Wall St originated memes in the industry. Solana Street Bets is a decentralized Solana meme coin inspired by the infamous /wallstreetbets subreddit.

SatoshiStreetBets

SatoshiStreetBets (SSB) is trending as community members discuss new coins launching on Phantom Wallet and those building momentum. Several coins, including $1DOG, $CHINAWINS, and $KABOOM, are generating significant buzz within the SSB community. Discussions also highlight projects focusing on community building and locked liquidity, reflecting a growing interest in projects prioritizing trust and transparency.

Lynas Rare Earths Ltd. engages in the production of rare earth minerals. It focuses on the exploration, development, mining, and processing of rare earth deposits. The company was founded by Nicholas Anthony Curtis on May 23, 1983 and is headquartered in Perth, Australia.

Lynas Rare Earths Limited

Lynas Rare Earths is trending due to potential US and Australian rare earth deals, with community members speculating on upcoming meetings and long-term supply agreements. Some investors are discussing the recent price drop as a profit-taking opportunity, while others highlight the company's strong fundamentals and increasing demand for rare earth materials. The community also discusses potential partnerships and expansions, especially the U.S. plant.

Aptera Motors Corp. is an automotive technology company focused on the development, production, and distribution of energy-efficient, solar-powered, battery-electric vehicles. Its flagship product, the Aptera, is a three-wheeled, two-seat solar vehicle designed to reduce reliance on traditional charging by utilizing integrated solar panels. The company was founded by Steve Fambro and Chris Anthony and is headquartered in San Diego, CA.

Aptera Motors Corp - Ordinary Shares - Class B

Aptera Motors Corp

Aptera Motors ($SEV) is trending due to its recent direct listing, which has been marked by extreme volatility and trading halts, sparking community debate about market manipulation. Discussions revolve around the company's long-term viability, production capabilities, and unique solar-powered vehicle design, with some comparing it to other EV companies. The community is actively questioning the stock's potential and speculating on future price movements.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

Delcath Systems is trending as investors discuss its future growth potential amid mixed sentiments around revenue guidance and a discount program impacting profitability. The community is actively analyzing the implications of the CHOPIN trial data expected at #esmo2025, which could significantly expand the use of their Hepzato Kit, and whether it might attract buyout interest. Discussions also involve revenue expectations, potential cash flow, and the impact of expanded clinical trials on the company's financial strategy.

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.

Tempest Therapeutics Inc

TPST is trending amid community speculation about a potential acquisition, fueled by upcoming industry events and chatter around Roche. Discussions revolve around buyout values, potential buyers, and the timing of a deal announcement, with many citing the approaching expiration of management options as a key deadline. The community is weighing the likelihood of a buyout against the backdrop of the company's financial situation and the broader oncology market.

Quantum Resistant Ledger is a cryptocurrency based on the Python programming language, aimed at combating future attacks by quantum computers. This cryptocurrency is the brainchild of Peter Waterland who realised that Bitcoin, Ethereum, and other such cryptocurrencies have no protection against future technology. It claims to be a “future-proof” cryptocurrency which enables transactions and decentralized communication while providing protection against classical as well as quantum computer attacks.  The Quantum Resistant Ledger company was founded by Peter Waterland, who found that Bitcoin, as well as Ethereum signatures are susceptible to attacks by powerful quantum computers. His research on quantum computers and signature programs let to the development of this new cryptocurrency, designed to be resistant to the present classical attacks as well as any future quantum computer attacks. Their team is made up of a diverse range of members spread out across the world, including developers (core, blockchain, mobile developers, etc.), analysts, advisors, marketing managers, designers and more.  Quantum Resistant Ledger is the first ever cryptocurrency and the only one in existence as of August 2018, to consider the threat that the future technology of quantum computing poses to cryptocurrencies and their working. It uses a technology specifically designed for post-quantum security, called XMSS, which makes it secure against powerful quantum computers even while using a Proof-of-Stake consensus mechanism. Security against cyber-attacks is a very serious concern in this digital age, especially when you have digital assets whose loss is likely to lead you to bankruptcy.  QRL is the first blockchain technology that provides durability and stability through resistance to quantum computer attacks. The encryption methods used by modern blockchains can become vulnerable to quantum computers over the next ten years. QRL tries to create a blockchain with long-term stability. By using blockchain technology, the QRL platform creates a “ledger” that generates hashes in such a way that it is virtually impenetrable to any type of computer attack.

Quantum Resistant Ledger 

Quantum Resistant Ledger is trending as discussions around quantum computing's potential impact on blockchain security intensify, particularly its threat to current encryption methods used by Bitcoin and other major cryptocurrencies. The community highlights QRL's quantum-resistant design from its inception in 2018, suggesting it as a hedge against future quantum attacks and anticipating potential listings on major exchanges. Recent news of advancements in quantum computing and government initiatives for quantum-resistant standards are fueling the conversation around QRL as a proactive solution.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visa ($V) is trending amid discussions around its strategic moves in stablecoins, AI-driven security, and partnerships, with some analysts anticipating a potential breakout. Community members are weighing the stock's potential against that of competitors and assessing its value in light of consumer spending trends. Several sources point to a potential earnings beat, although some express concern about the stock's recent performance.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound ($COMP) is trending as traders debate its next move, with some anticipating a breakout while others foresee a price dump. Community discussions revolve around potential short squeezes and the impact of dilution on the token's value. Amidst the volatility, some investors express optimism, citing the low supply and potential for a significant upward swing.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending as investors discuss its potential for acquisition following strategic moves like the Recordati partnership and new data presentations at the European Society of Cardiology (ESC) Congress. The community highlights the company's restructured financials, a strong patent portfolio, and identified synergies, interpreting these factors as signs of increased attractiveness to potential acquirers. Discussions also involve potential combination therapies and ongoing patent litigation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CHMP Recommends EU Approval of BRINSUPRI (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

CHMP Recommends EU Approval of BRINSUPRI (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis CHMP Recommends EU Approval of BRINSUPRI (brensocatib) for the Treatment of Non-Cystic...

Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025

Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025 Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the...

Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025

Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025 Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025 PR...

Top Stock Reports for AMD, Abbott & Micron Technology

AMD, Abbott and Micron shine in fresh Zacks reports, highlighting AI momentum, product pipelines and strong financial positioning.

Is IPF the Next Big Market Opportunity for United Therapeutics?

UTHR reports strong TETON-2 results for Tyvaso in IPF, showing lung function gains and eyeing a major new market.

Top Analyst Reports for Microsoft, Amazon.com & Philip Morris

Microsoft, Amazon.com and Philip Morris headline fresh analyst reports highlighting AI, cloud, and smoke-free growth momentum.

UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals

United Therapeutics hit a record high after its Tyvaso study in idiopathic pulmonary fibrosis met key goals and showed broad patient benefits.

Electromed traded higher after hours on Tuesday as management highlighted hospital market share gains from a “distracted rival”, a strategy they credited with contributing to the company’s 11th straight quarter of year-over-year revenue and profit growth.The stock closed up 2.3% at $20.66 on Tuesday and jumped another 12.6% after hours following its earnings release.The maker of the SmartVest airway clearance system reported record fourth-quarter revenue of $17.4 million, up 17% from last year, as profit rose 21% to $2.2 million, or $0.25 a share.&nbsp;On the earnings call, Electromed detailed growth drivers beyond the headline numbers. Executives said hospitals are proving to be a “gateway” channel as patients introduced to SmartVest in care settings are often discharged with prescriptions for home use.&nbsp;CEO Jim Cunniff added that a major competitor with an “older product” is internally distracted, creating opportunities for market share growth.The company also highlighted strong e-prescribe adoption, with 38% of orders now submitted digitally, resulting in a halving of&nbsp;fulfillment times. A new Salesforce-based CRM integrating sales and reimbursement teams has also been rolled out, earning positive early feedback.&nbsp;Productivity gains continue, with sales&nbsp;representatives averaging $1.06 million each in annual revenue, up from $850,000 three years ago. Expansion to 61 territories is planned for FY26.Electromed is also benefiting from greater awareness of bronchiectasis after Insmed’s new drug launch, which executives said is raising disease visibility without competing on airway clearance.&nbsp;Earlier this month, the U.S. Food and Drug Administration (FDA)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/insmed-announces-fda-approval-for-drug-to-treat-chronic-lung-disease/chrxJPSRdJk">approved Insmed’s Brinsupri</a>, an oral once-daily treatment, as the first and only FDA-approved therapy for non-cystic fibrosis bronchiectasis (NCFB).&nbsp;The drug is cleared for use in adults and children aged 12 and older.&nbsp;Electromed noted over 31,000 visits to its bronchiectasis campaign site and cited registry data showing 58% of patients meeting criteria for HFCWO therapy remain untreated, a gap it sees as a major market opportunity.On Stocktwits, retail sentiment for Electromed was ‘bullish’ amid ‘high’ message volume.<a href="https://stocktwits.com/symbol/ELMD">Electromed’s stock</a> has declined over 30% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Electromed’s stock (ELMD) has declined over 30% so far in 2025. (Photo credit: Getty Images)

Why Electromed Stock Jumped 12% After-Hours: A Rival’s Weakness And A New Drug Tailwind

The after-hours surge came as management pointed to hospital market share gains from a distracted competitor and rising bronchiectasis awareness following Insmed’s FDA-approved drug launch.

Equity

H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the shares after the firm’s Brinsupri got approved as a treatment for non-cystic fibrosis bronchiectasis (NCFB).The new price target of $240 represents a near 97% upside to INSM’s closing price on Tuesday.H.C. Wainwright sees Insmed as "poised to join the ranks" of Roche's (RHHBY) Genentech and Pfizer's (PFE) Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy, said the analyst. Wainwright believes that Brinsupri and its next-generation versions will be able to treat a broad range of neutrophil-mediated diseases.Given the approval and potential for a "pipeline-in-a-pill", the firm now includes chronic rhinosinusitis without nasal polyps (CRSsNP) and hidradenitis suppurativa (HS) indications in its valuation, assuming a launch by 2027 for CRSsNP and a launch by 2028 for HS.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/INSM">Insmed</a> trended in the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1252/120;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_13_at_1_21_34_PM_png_eb547ea1d1.webp" alt="INSM's Sentiment Meter and Message Volume as of 1:21 p.m. ET on Aug. 13, 2025 | Source: Stocktwits" width="1252" height="120"><figcaption>INSM's Sentiment Meter and Message Volume as of 1:21 p.m. ET on Aug. 13, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the shares to hit $150 by the end of the week.<stembedurl>https://stocktwits.com/king9885/message/624942721</stembedurl>Brinsupri, an oral, once-daily treatment, is now the first and only FDA-approved treatment for NCFB. It was <a href="https://stocktwits.com/news-articles/markets/equity/insmed-announces-fda-approval-for-drug-to-treat-chronic-lung-disease/chrxJPSRdJk">approved</a> on Tuesday for adults as well as children aged 12 years and older.Bronchiectasis is a serious, chronic lung disease that causes airways to permanently widen due to a cycle of infection, inflammation, and lung tissue damage. Symptoms include chronic cough, excessive sputum production, shortness of breath, and repeated respiratory infections, which can worsen the underlying condition. A hallmark of bronchiectasis is frequent exacerbations, or flares, when symptoms worsen.In a late-stage study, patients taking Brinsupri 10 mg or 25 mg had a 21.1% and 19.4% reduction in the annual rate of exacerbations, respectively, as compared to placebo. Both dosage strengths of Brinsupri also significantly prolonged the time to first exacerbation.INSM stock is up by 76% this year and by 59% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/reshape-lifesciences-stock-rockets/chrC0AtRd9N">ReShape Lifesciences Stock Rocketed 61% Today – Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Insmed Incorporated logo is seen displayed on a smartphone. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week

The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy.

Insmed shares got a wave of bullish calls Tuesday after U.S. regulators cleared its new drug Brinsupri, the first treatment approved for non-cystic fibrosis bronchiectasis (NCFB).&nbsp;The stock jumped 8.1% on Tuesday, closing at&nbsp;its highest level in nearly 25 years before slipping 0.6% in after-hours trading.The once-a-day oral medicine is approved for adults and children 12 and older, offering a new option for patients with a condition that has had no dedicated therapies until now.NCFB is a long-term lung disease that causes permanent widening of the airways, driven by a cycle of infection, inflammation, and tissue damage. Symptoms include chronic cough,&nbsp;excessive mucus production, shortness of breath, and frequent infections, which can lead to exacerbations.&nbsp;In the U.S., Europe, and Japan, Insmed estimates the addressed patient population at 500,000, 600,000, and 150,000 diagnosed patients, respectively.Approval was based on late- and mid-stage data, in which Brinsupri reduced annual flare-ups by 21.1% at the 10 mg dose and 19.4% at the 25 mg dose compared to placebo. Both doses also delayed the time to&nbsp;the first flare.&nbsp;Applications have already been filed in Europe and the U.K., with a submission in Japan planned for 2025. If cleared overseas, Insmed expects to launch in those markets starting in 2026.Wells Fargo’s Tiago Fauth raised his price target to $140 from $130 and maintained an ‘Overweight’ rating, noting that approval had been expected, but the higher-end pricing could help the drug reach a market worth over $5 billion.&nbsp;RBC Capital’s team raised its target to $138 from $120 and called the label “a best-case scenario,” noting that both doses were approved without major warnings, key trial endpoints were met, and there was no exacerbation cutoff. They see the U.S. market at $3.8 billion and the global opportunity topping $6 billion.Meanwhile, Bank of America stuck with its $121 target and ‘Buy’ rating, saying the label contained no surprises. While approval is a major milestone, the bank said the bigger question now is whether Insmed can deliver on its own $5 billion peak sales projection.On Stocktwits, retail sentiment for Insmed was ‘extremely bullish’ amid a 340% surge in 24-hour message volume.One user remarked that Insmed looked like a strong long-term hold, predicting a major growth phase ahead and noting that many patients have no alternatives. They added that with minimal side effects or warnings, the drug could more easily be used for other conditions.<stembedurl>https://stocktwits.com/InvestorWisdom/message/624897660</stembedurl>Another user called the FDA label “a thing of beauty,” saying it effectively doubled the addressable market for non-cystic fibrosis bronchiectasis.&nbsp;They described the decision as a “grand slam” for the company, suggesting it could take off further if upcoming BiRCH trial results confirm Brinsupri’s broader potential.<stembedurl>https://stocktwits.com/JoeB07/message/624878902</stembedurl>Insmed’s stock has risen 76.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstatic

Insmed shares surged after U.S. regulators approved Brinsupri, the first treatment for non-cystic fibrosis bronchiectasis.

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Insmed Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$165.76
Prev Close	$163.19
Open	$163.80
Dividend Yield	0.00%
50-Day Moving Average	$142.85
Beta	0.82
Avg. Volume	2.26M
PE Ratio	-29.06

52-Week High	$166.44
52-Week Low	$60.40
Market Capitalization	$35.04B
EPS (Annual)	-$5.57
Price to Book	28.00
Revenue Per Employee	$286,158.14
Enterprise Value/EBITDA	N/A

INSM
Insmed Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INSM News

INSMInsmed Inc